ClinicalTrials.gg
CompletedNCT05943509Updated Oct 2, 2026

Hearing Program in Primary Care

An interventional study of Alternative rehabilitation strategies and Usual Care in Deafness, sponsored by NYU Langone Health. Completed at 1 site in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment

How we know

Updated Oct 2, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Deafness with a site in United States — 19 open to participants now, 22 under way, 1 of them phase 3. Deafness · United States.

Enrollment
9th of 44
120 · median 41
Started
2024
with 4 others
No phase
31 of 63
10 open now
Registered
52nd of 63
by date
Lead sponsor
5 of 63
NYU Langone Health

Among the 63 studies in Deafness with a site in United States, this one is the 9th largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2024, is one of 31 with no phase, and was the 52nd registered.

Deafness

161 studies on the registry are indexed under Deafness; 46 are open to participants now.

Browse Deafness studies →

Open to participants now

19 of the 63 studies in Deafness with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Deafness studies recruiting now, 11 (37%) set no upper age limit and 10 (33%) stop at 75 or younger; 19 take children under 18; 5 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Deafness with a site in United States, or all of them as a file.
02

Study summary

During a primary care visit, investigators will screen and identify participants with hearing loss and then randomize to a) counseling on accessible assistive listening devices or b) referral to traditional audiology care pathway alone.

03

Conditions studied

  • Deafness

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • speaks English or Spanish;
  • capacity to consent to research

Exclusion criteria

Exclusion Criteria:

  • has or uses hearing aids or cochlear implants
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Alternative Rehabilitation Strategies

    Patients who screened positive for hearing loss and were randomized into the counselling on alternative rehabilitation strategies intervention arm.

    Behavioral: Alternative rehabilitation strategies

  • Active comparator
    Usual Care

    Patients who screened positive for hearing loss and were randomized into the usual care audiology pathway control arm alone.

    Behavioral: Usual Care

Interventions

  • BehavioralAlternative rehabilitation strategies

    Counseling intervention.

  • BehavioralUsual Care

    Usual care audiology pathway.

06

What researchers measure

Primary outcomes

  1. Number of Potential Participants Approached

    Time frame: Up to Month 3

  2. Number of Potential Participants Screened

    Time frame: Up to Month 3

  3. Percentage of Screened Participants with Hearing Loss

    Time frame: Up to Month 3

Secondary outcomes

  1. Percentage of Intervention Arm Participants who Complete Counseling Session

    Time frame: Up to Month 3

  2. Percentage of Participants who Respond to Outreach to Confirm Recommendations within 72 Hours

    Time frame: Up to Month 3

  3. Percentage of Participants who Respond to 3-Month Follow-Up

    Time frame: Month 3

07

Study locations

1 site
  • NYC H+H/Bellevue
    New York, New York 10016, United States
08

References and documents

Publications

  • Friedmann DR, Diminich LN, Spitzer ER, Ajmal S, Weinstein B, Dickson V, Goldfeld KS, Chodosh J. Study protocol: feasibility of a hearing program in primary care for underserved older adults. Pilot Feasibility Stud. 2026 Feb 24;12(1):68. doi: 10.1186/s40814-026-01773-2. PubMed 41736137 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: David.friedmann@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to David.friedmann@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Aug 2025, 18 months.

Of 50 non-industry interventional studies with no phase under Deafness, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20. This study's 18 months is below that.

Counting every sponsor, half of 58 studies reached it within 31 months; a quarter within 17.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Jan 2026 → Aug 2025 and completion Jan 2026 → Nov 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2023
First posted
Jul 13, 2023
StartActual
Feb 15, 2024
Primary completionActual
Aug 18, 2025was Jan 2026
CompletionActual
Nov 12, 2025was Jan 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 2, 2026
Primary completion
Jan 15, 2026→Aug 18, 2025 (actual)
Oct 2, 2026
Study completion
Jan 15, 2026→Nov 12, 2025 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Active, not recruiting→Completed
    Primary completion Jan 15, 2026→Aug 18, 2025 (now actual)
    Study completion Jan 15, 2026→Nov 12, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05943509
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Jul 13, 2023
Start date
Feb 15, 2024
Primary completion
Aug 18, 2025
Completion
Nov 12, 2025
Last update
Oct 2, 2026

Study contacts

David Friedmann
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion